JP2013531681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531681A5 JP2013531681A5 JP2013518858A JP2013518858A JP2013531681A5 JP 2013531681 A5 JP2013531681 A5 JP 2013531681A5 JP 2013518858 A JP2013518858 A JP 2013518858A JP 2013518858 A JP2013518858 A JP 2013518858A JP 2013531681 A5 JP2013531681 A5 JP 2013531681A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- functional variant
- nucleic acid
- use according
- e4orf1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 102000004169 proteins and genes Human genes 0.000 claims 24
- 150000007523 nucleic acids Chemical group 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 8
- 238000001415 gene therapy Methods 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 8
- 238000001890 transfection Methods 0.000 claims 8
- 241000701161 unidentified adenovirus Species 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 229920002307 Dextran Polymers 0.000 claims 4
- 108091061960 Naked DNA Proteins 0.000 claims 4
- 241001068295 Replication defective viruses Species 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 4
- 239000001506 calcium phosphate Substances 0.000 claims 4
- 235000011010 calcium phosphates Nutrition 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000005684 electric field Effects 0.000 claims 4
- 238000004520 electroporation Methods 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000001938 protoplast Anatomy 0.000 claims 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 230000006798 recombination Effects 0.000 claims 3
- 238000005215 recombination Methods 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 2
- 208000027700 hepatic dysfunction Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36244310P | 2010-07-08 | 2010-07-08 | |
| US61/362,443 | 2010-07-08 | ||
| PCT/US2011/043338 WO2012006512A1 (en) | 2010-07-08 | 2011-07-08 | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531681A JP2013531681A (ja) | 2013-08-08 |
| JP2013531681A5 true JP2013531681A5 (enExample) | 2014-08-21 |
| JP5965397B2 JP5965397B2 (ja) | 2016-08-03 |
Family
ID=44629893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518858A Expired - Fee Related JP5965397B2 (ja) | 2010-07-08 | 2011-07-08 | 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8951980B2 (enExample) |
| EP (1) | EP2590665B1 (enExample) |
| JP (1) | JP5965397B2 (enExample) |
| KR (1) | KR101831638B1 (enExample) |
| CN (1) | CN103052397B (enExample) |
| AU (1) | AU2011274537B9 (enExample) |
| CA (1) | CA2803787C (enExample) |
| ES (1) | ES2550962T3 (enExample) |
| NZ (1) | NZ606236A (enExample) |
| TW (1) | TWI531650B (enExample) |
| WO (1) | WO2012006512A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618374T3 (es) | 2012-10-17 | 2017-06-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Composiciones y métodos para mejorar la absorción de glucosa |
| US9354963B2 (en) * | 2014-02-26 | 2016-05-31 | Microsoft Technology Licensing, Llc | Service metric analysis from structured logging schema of usage data |
| WO2015164312A1 (en) | 2014-04-23 | 2015-10-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | SMALL MOLECULE ANALOGS OF E4orf1 |
| GB201910299D0 (en) * | 2019-07-18 | 2019-09-04 | Aouadi Myriam | Medical uses, methods and uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1626280B1 (en) * | 2004-08-12 | 2007-02-14 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
| US20060045919A1 (en) | 2004-08-27 | 2006-03-02 | Samueli Institute | Homeopathic compositions and methods for the treatment of cancer |
| JP2008105945A (ja) * | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
| EP1954131B1 (en) * | 2005-11-30 | 2014-04-02 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Adenovirus 36 e4 orf 1 gene and protein and their uses |
| AU2006342053A1 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| JP2008273938A (ja) * | 2007-03-30 | 2008-11-13 | Shiseido Co Ltd | アディポネクチン産生促進剤 |
-
2011
- 2011-07-08 CA CA2803787A patent/CA2803787C/en not_active Expired - Fee Related
- 2011-07-08 US US13/178,986 patent/US8951980B2/en not_active Expired - Fee Related
- 2011-07-08 CN CN201180033866.7A patent/CN103052397B/zh not_active Expired - Fee Related
- 2011-07-08 EP EP11741354.2A patent/EP2590665B1/en not_active Not-in-force
- 2011-07-08 TW TW100124173A patent/TWI531650B/zh not_active IP Right Cessation
- 2011-07-08 KR KR1020137001869A patent/KR101831638B1/ko not_active Expired - Fee Related
- 2011-07-08 ES ES11741354.2T patent/ES2550962T3/es active Active
- 2011-07-08 WO PCT/US2011/043338 patent/WO2012006512A1/en not_active Ceased
- 2011-07-08 AU AU2011274537A patent/AU2011274537B9/en not_active Ceased
- 2011-07-08 NZ NZ606236A patent/NZ606236A/en not_active IP Right Cessation
- 2011-07-08 JP JP2013518858A patent/JP5965397B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-06 US US14/590,262 patent/US20170340699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amet et al. | Human growth hormone–transferrin fusion protein for oral delivery in hypophysectomized rats | |
| Kaur et al. | Modified mRNA as a therapeutic tool for the heart | |
| US20180258429A1 (en) | Sarna compositions and methods of use | |
| JP2017514483A5 (enExample) | ||
| Duan et al. | Exosome-mediated drug delivery for cell-free therapy of osteoarthritis | |
| WO2015075557A2 (en) | C/ebp alpha compositions and methods of use | |
| JP2019523648A5 (enExample) | ||
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| WO2018021855A1 (ko) | Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물 | |
| JP2013531681A5 (enExample) | ||
| Xie et al. | Pulmonary delivery of siRNA via polymeric vectors as therapies of asthma | |
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| EP2822600A1 (en) | Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders | |
| Chen et al. | Using RNA therapeutics to promote healthy aging | |
| ES2559106B1 (es) | Método de activación de la expresión del gen Pitx2 para promover la regeneración muscular | |
| Janssen et al. | Gene based therapies for kidney regeneration | |
| WO2014027608A1 (ja) | 褐色脂肪細胞分化誘導剤 | |
| CN118374495A (zh) | 一种抑制NLRP3基因表达的siRNA及其前体和应用 | |
| McCarthy et al. | Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy | |
| Hirose et al. | Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes | |
| JP2015505535A5 (enExample) | ||
| CN116507721A (zh) | 构建溶瘤病毒的方法 | |
| WO2021115141A1 (zh) | 一种抑制HTT基因表达的siRNA及其前体和应用 | |
| Ogris | Nucleic acid based therapeutics for tumor therapy | |
| Ni et al. | Enhanced delivery of human growth hormone across cell membrane by Tat-PTD |